TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36246941

Group type: EXPERIMENTAL
Intervention: Faricimab 6.0 mg up to every 16 weeks after 4 initial every-4-week doses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aflibercept 2.0 mg every 8 weeks after 3 initial every-4-week doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Faricimab with personalized treatment interval (PTI)
Number of subjects: 0
Study: 36247059

Group type: EXPERIMENTAL
Intervention: Mandibular overdentures assisted by two ultrashort implants with PBM therapy (Dose A: 3.75 J/cm²)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mandibular overdentures assisted by four ultrashort implants with PBM therapy (Dose A: 3.75 J/cm²)
Number of subjects: 12

Group type: COMPARATOR
Intervention: PBM therapy (Dose A: 3.75 J/cm²)
Number of subjects: 12

Group type: COMPARATOR
Intervention: PBM therapy (Dose B: not specified)
Number of subjects: 12
Study: 36247444

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) using J-Valve system for 4 patients with pure aortic regurgitation and Venus-A system for 1 patient with severe aortic stenosis.
Number of subjects: 5
Study: 36247452

Group type: EXPERIMENTAL
Intervention: 2010 WHO guidelines (≥30 min moderate- to vigorous-intensity PA at ≥ 10-min bout duration)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: 2020 WHO guidelines (≥30 min of MVPA of any bout duration)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Daily steps ≥7,500
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Daily steps ≥10,000
Number of subjects: 282
Study: 36247455

Group type: EXPERIMENTAL
Intervention: Wearable activity trackers to monitor physical activity (PA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Accelerometer data collection for 18 days post-discharge and 14 days at one-year follow-up
Number of subjects: 0
Study: 36247744

Group type: EXPERIMENTAL
Intervention: FDC formulation containing raloxifene 60 mg and cholecalciferol 800 IU
Number of subjects: 46

Group type: COMPARATOR
Intervention: Co-administration of raloxifene and cholecalciferol
Number of subjects: 46
Study: 36247751

Group type: EXPERIMENTAL
Intervention: VEGF/CITED2 ratio from peripheral blood mononuclear cells (PBMCs)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Binary logistic regression analysis
Number of subjects: 67
Study: 36247749

Group type: EXPERIMENTAL
Intervention: Low ankle-brachial index (ABI) ≤0.9
Number of subjects: 325

Group type: COMPARATOR
Intervention: Normal ankle-brachial index (ABI) >0.9
Number of subjects: 325
Study: 36247822

Group type: EXPERIMENTAL
Intervention: 10 mg lutein, 2 mg zeaxanthin, and 10 mg meso-zeaxanthin
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 36247923

Group type: EXPERIMENTAL
Intervention: Ramucirumab 8 mg/kg intravenously Q2W
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Ramucirumab
Number of subjects: 104
Study: 36247958

Group type: EXPERIMENTAL
Intervention: SuperJump activity (exercise group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Non-exercise group (control group)
Number of subjects: 24
Study: 36248000

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction + Computerized Cognitive Training (CCT)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Physical Exercise (PE) + Computerized Cognitive Training (CCT)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Training (CCT)
Number of subjects: 141
Study: 36248617

Group type: EXPERIMENTAL
Intervention: BNT162b2 mRNA COVID-19 vaccine (two doses)
Number of subjects: 378
Study: 36248865

Group type: EXPERIMENTAL
Intervention: Neoantigen vaccination after local RFA treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Neoantigen vaccination without prior RFA treatment
Number of subjects: 28
Study: 36249001

Group type: EXPERIMENTAL
Intervention: Virtual Reality Experience (VRE)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control
Number of subjects: 44
Study: 36249475

Group type: EXPERIMENTAL
Intervention: Apple Watch Series 6
Number of subjects: 24

Group type: COMPARATOR
Intervention: Masimo Radical-7
Number of subjects: 24
Study: 36249526

Group type: EXPERIMENTAL
Intervention: Citalopram (single dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 36249705

Group type: EXPERIMENTAL
Intervention: GEM103 (Recombinant Human Complement Factor H) at doses of 50 μg/eye, 100 μg/eye, 250 μg/eye, or 500 μg/eye
Number of subjects: 12
Study: 36249765

Group type: EXPERIMENTAL
Intervention: Preoperative duloxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study: 36250171

Group type: EXPERIMENTAL
Intervention: Faecal calprotectin (fCAL) in PSC-IBD
Number of subjects: 48

Group type: COMPARATOR
Intervention: Faecal calprotectin (fCAL) in UC
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Faecal calprotectin (fCAL) in PSC-IBD (quiescent colitis)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Risk of biliary complications in PSC-IBD
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Correlation of fCAL with biliary calprotectin
Number of subjects: 48
Study: 36250418

Group type: EXPERIMENTAL
Intervention: Adjunctive therapies plus land-based exercise therapy
Number of subjects: 6508

Group type: EXPERIMENTAL
Intervention: Adjunctive electrophysical agents plus exercise
Number of subjects: 6508

Group type: EXPERIMENTAL
Intervention: Adjunctive therapies plus exercise
Number of subjects: 6508
Study: 36250577

Group type: EXPERIMENTAL
Intervention: C-reactive protein point-of-care test
Number of subjects: 10218

Group type: EXPERIMENTAL
Intervention: Procalcitonin point-of-care test
Number of subjects: 10218

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 10218
Study: 36251174

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN)
Number of subjects: 1821
Study: 36251211

Group type: EXPERIMENTAL
Intervention: High-grade adenocarcinoma patients
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Median time to brain metastasis
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Median time to non-brain metastasis
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Median survival after first progression (brain metastasis)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Median survival after first progression (non-brain metastasis)
Number of subjects: 85
Study: 36251220

Group type: EXPERIMENTAL
Intervention: Cemiplimab monotherapy (350 mg every 3 weeks intravenously)
Number of subjects: 295
Study: 36251223

Group type: EXPERIMENTAL
Intervention: Hypothermia at 33 °C
Number of subjects: 581

Group type: COMPARATOR
Intervention: Controlled normothermia at 37 °C
Number of subjects: 581
Study: 36251376

Group type: EXPERIMENTAL
Intervention: Nutritional supplement
Number of subjects: 20

Group type: COMPARATOR
Intervention: No nutritional supplement (Control)
Number of subjects: 20
Study: 36251401

Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplantation (alloHCT)
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Functional Assessment of Cancer Therapy-General (FACT-G), SF-36, EQ-5D
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Baseline PRO scores
Number of subjects: 384
Study: 36251466

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36251488

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36251503

Group type: EXPERIMENTAL
Intervention: Isatuximab (Isa) + Cemiplimab (Cemi)
Number of subjects: 58
Study: 36251766

Group type: EXPERIMENTAL
Intervention: ORADUR-Methylphenidate, dosage and duration not available
Number of subjects: 0
Study: 36251868

Group type: EXPERIMENTAL
Intervention: Complementary approaches
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 36252092

Group type: EXPERIMENTAL
Intervention: CT perfusion or magnetic resonance imaging selection for thrombectomy
Number of subjects: 715

Group type: COMPARATOR
Intervention: Noncontrast CT selection for thrombectomy
Number of subjects: 715
Study: 36252116

Group type: EXPERIMENTAL
Intervention: Machine Learning score integrating CCTA-based quantitative plaque features
Number of subjects: 208

Group type: COMPARATOR
Intervention: Visual stenosis grade
Number of subjects: 208

Group type: COMPARATOR
Intervention: Standard CCTA stenosis evaluation
Number of subjects: 208

Group type: COMPARATOR
Intervention: FFR
Number of subjects: 208
Study: 36252167

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 1873

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1873
Study: 36252241

Group type: EXPERIMENTAL
Intervention: Social distancing adherence
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Increased alcohol use
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: EQ-VAS score
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Clinically relevant depressive symptoms (PHQ-9 score ≥10)
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Worrying about contracting COVID-19
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Having ≥3 comorbidities
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Finding social distancing easy
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Age younger than 60 years
Number of subjects: 499
Study: 36252397

Group type: EXPERIMENTAL
Intervention: M. tuberculosis H37Rv
Number of subjects: 30

Group type: COMPARATOR
Intervention: M. bovis BCG
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: M. tuberculosis H37Rv and M. bovis BCG
Number of subjects: 30
Study: 36252414

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA) diagnosis
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mild OSA
Number of subjects: 60

Group type: COMPARATOR
Intervention: No OSA
Number of subjects: 60
Study: 36252789

Group type: EXPERIMENTAL
Intervention: Two doses of mRNA COVID-19 vaccine
Number of subjects: 4091

Group type: EXPERIMENTAL
Intervention: Three doses of mRNA COVID-19 vaccine
Number of subjects: 4091
Study: 36252805

Group type: EXPERIMENTAL
Intervention: Malaria in pregnancy (MIP)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Preterm birth, low birthweight, increasing maternal education level, and increasing interleukin 6 levels
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Severe neurocognitive delay
Number of subjects: 307
Study: 36252870

Group type: EXPERIMENTAL
Intervention: ML EGD (machine learning-based model)
Number of subjects: 2794

Group type: COMPARATOR
Intervention: Baveno VI criteria
Number of subjects: 2794
Study: 36252998

Group type: EXPERIMENTAL
Intervention: T-DM1 plus pembrolizumab (3.6 mg/kg T-DM1 every 21 days plus 200 mg pembrolizumab every 21 days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: T-DM1 plus pembrolizumab
Number of subjects: 20
Study: 36253275

Group type: EXPERIMENTAL
Intervention: Epithelial cytokines that elicit ILC2 activation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neural signals from sympathetic, parasympathetic, sensory, and enteric fibers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neuro-epithelial-ILC2 crosstalk
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disturbed ILC2-centered neuro-epithelial-immune cell interactions
Number of subjects: 0
Study: 36253296

Group type: EXPERIMENTAL
Intervention: Out-of-hospital ECG interpretation
Number of subjects: 2122

Group type: EXPERIMENTAL
Intervention: Expert interpretation of serial ECG changes
Number of subjects: 2122

Group type: EXPERIMENTAL
Intervention: Artificial intelligence-augmented out-of-hospital ECG
Number of subjects: 2122

Group type: COMPARATOR
Intervention: ED ECG interpretation
Number of subjects: 2122
Study: 36253295

Group type: EXPERIMENTAL
Intervention: Tele-ED care
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: Tele-ED care (subgroup of advanced practice providers)
Number of subjects: 1191
Study: 36253484

Group type: EXPERIMENTAL
Intervention: Talazoparib
Number of subjects: 20
Study: 36253663

Group type: EXPERIMENTAL
Intervention: 2-[
Number of subjects: 24
Study: 36253829

Group type: EXPERIMENTAL
Intervention: Insertion of a ventilation tube into the tympanic membrane
Number of subjects: 104

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 104
Study: 36253834

Group type: EXPERIMENTAL
Intervention: Tobacco dependence treatment (TDT) intervention counseling
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Implementation strategies (training and system changes)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pilot study intervention
Number of subjects: 16
Study: 36253875

Group type: EXPERIMENTAL
Intervention: Multidisciplinary assessment and standardized treatment
Number of subjects: 3241

Group type: COMPARATOR
Intervention: Microsurgery
Number of subjects: 3241

Group type: COMPARATOR
Intervention: Embolization
Number of subjects: 3241

Group type: COMPARATOR
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 3241

Group type: COMPARATOR
Intervention: Combination of embolization and SRS
Number of subjects: 3241

Group type: COMPARATOR
Intervention: Conservation
Number of subjects: 3241

Group type: EXPERIMENTAL
Intervention: Follow-up assessments
Number of subjects: 3241
Study: 36253882

Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (TAF)
Number of subjects: 89
Study: 36253968

Group type: EXPERIMENTAL
Intervention: Low ω-3 index (≤3.70%)
Number of subjects: 832
Study: 36254201

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus Bevacizumab
Number of subjects: 371

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 371
Study: 36254733

Group type: EXPERIMENTAL
Intervention: Renal pelvic denervation
Number of subjects: 18
Study: 36254918

Group type: EXPERIMENTAL
Intervention: Post-CPB GLS
Number of subjects: 72

Group type: COMPARATOR
Intervention: Pre-CPB GLS
Number of subjects: 72

Group type: COMPARATOR
Intervention: Change in GLS
Number of subjects: 72
Study: 36255027

Group type: EXPERIMENTAL
Intervention: Wet suction technique (WEST)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard suction technique (SST)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Slow-pull technique (SPT)
Number of subjects: 300
Study: 36255231

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd)
Number of subjects: 24
Study: 36255258

Group type: EXPERIMENTAL
Intervention: Gepotidacin (doses of ≤300 mg/kg/day and ≤1,250 mg/kg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gepotidacin (1,000 mg/kg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gepotidacin (highest tolerated dose of 300/1,250 mg/kg/day)
Number of subjects: 0
Study: 36255372

Group type: EXPERIMENTAL
Intervention: Eltrombopag (ELT) monotherapy
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Lenalidomide (LEN) monotherapy
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both Eltrombopag (ELT) and Lenalidomide (LEN)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Eltrombopag (ELT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Lenalidomide (LEN)
Number of subjects: 52
Study: 36255391

Group type: EXPERIMENTAL
Intervention: Nivolumab and Temozolomide
Number of subjects: 28
Study: 36255444

Group type: EXPERIMENTAL
Intervention: Appetite traits mediation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36255448

Group type: EXPERIMENTAL
Intervention: Oral Ibrexafungerp
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36255609

Group type: EXPERIMENTAL
Intervention: GHD-CTB-Child
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: GHD-CTB-Observer
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: GHD-PTB
Number of subjects: 243
Study: 36256599

Group type: EXPERIMENTAL
Intervention: Venglustat 15 mg once-daily in combination with imiglucerase enzyme replacement therapy
Number of subjects: 11
Study: 36256671

Group type: EXPERIMENTAL
Intervention: Colchicine 0.05 mg/kg orally once daily before or after collagenase-induced ICH
Number of subjects: 0
Study: 36256693

Group type: EXPERIMENTAL
Intervention: Transcatheter PVL closure procedures on mitral valves
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Transcatheter PVL closure procedures on aortic valves
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Transcatheter PVL closure in symptomatic patients
Number of subjects: 216
Study: 36256698

Group type: EXPERIMENTAL
Intervention: 3M-TAVR
Number of subjects: 351

Group type: COMPARATOR
Intervention: S3i (conventional TAVR)
Number of subjects: 351
Study: 36256728

Group type: EXPERIMENTAL
Intervention: Hepatic T1-times in patients (590±89 ms)
Number of subjects: 1075

Group type: COMPARATOR
Intervention: Hepatic T1-times in controls (574±45 ms)
Number of subjects: 1075

Group type: EXPERIMENTAL
Intervention: Hepatic T1-time >610 ms
Number of subjects: 1075
Study: 36256783

Group type: EXPERIMENTAL
Intervention: Computer-aided triaging (CAT)
Number of subjects: 2901

Group type: EXPERIMENTAL
Intervention: Computer-aided diagnosis (CAD)
Number of subjects: 2901

Group type: EXPERIMENTAL
Intervention: Combined CAT and CAD
Number of subjects: 2901

Group type: COMPARATOR
Intervention: Radiological reading alone
Number of subjects: 2901

Group type: EXPERIMENTAL
Intervention: Computer-aided triaging (CAT) and CAD
Number of subjects: 2901
Study: 36256988

Group type: EXPERIMENTAL
Intervention: Family Constellation Therapy
Number of subjects: 102
Study: 36257062

Group type: EXPERIMENTAL
Intervention: 68 Ga-FAPI-46 PET/CT
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 18 F-FDG PET/CT
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group (9 non-COVID-19 patients)
Number of subjects: 6
Study: 36257718

Group type: EXPERIMENTAL
Intervention: COVID-19 pandemic period (March 1, 2020, to February 28, 2021)
Number of subjects: 287348

Group type: COMPARATOR
Intervention: Pre-pandemic period (March 1, 2019, to February 29, 2020)
Number of subjects: 287348

Group type: EXPERIMENTAL
Intervention: COVID-19 pandemic period
Number of subjects: 287348
Study: 36257978

Group type: EXPERIMENTAL
Intervention: Occupational lead exposure assessment in the SPHERL study
Number of subjects: 0
Study: 36258056

Group type: EXPERIMENTAL
Intervention: Children with BPD
Number of subjects: 45

Group type: COMPARATOR
Intervention: Children without BPD
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 45
Study: 36258166

Group type: EXPERIMENTAL
Intervention: Maternal body mass index
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Birth weight
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 402
Study: 36258240

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL)
Number of subjects: 274
Study: 36258239

Group type: EXPERIMENTAL
Intervention: COVID-19 patients with HABSI
Number of subjects: 829
Study: 36259253

Group type: EXPERIMENTAL
Intervention: Lazertinib as consolidation therapy
Number of subjects: 0
Study: 36259388

Group type: EXPERIMENTAL
Intervention: Ventricular Assist Device (VAD) or transplant
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Death
Number of subjects: 377

Group type: COMPARATOR
Intervention: Black race
Number of subjects: 377
Study: 36259411

Group type: EXPERIMENTAL
Intervention: Urban areas (thrombectomy-capable centers)
Number of subjects: 920

Group type: COMPARATOR
Intervention: Nonurban areas
Number of subjects: 920

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 920
Study: 36259527

Group type: EXPERIMENTAL
Intervention: Dolutegravir Immediate (DTG-I)
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Dolutegravir Delayed (DTG-D)
Number of subjects: 412

Group type: COMPARATOR
Intervention: Protease Inhibitors (Control)
Number of subjects: 412
Study: 36259971

Group type: EXPERIMENTAL
Intervention: B7-H3 CAR T cells, administered as 40 infusions, repeated locoregional dosing.
Number of subjects: 3
Study: 36260160

Group type: EXPERIMENTAL
Intervention: Informal social control
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 143
Study: 36260381

Group type: EXPERIMENTAL
Intervention: Fit&Sober app
Number of subjects: 22
Study: 36260765

Group type: EXPERIMENTAL
Intervention: Hematopoietic cell transplantation (HCT)
Number of subjects: 692
Study: 36260792

Group type: EXPERIMENTAL
Intervention: 1.5% ruxolitinib cream applied twice daily for 24 weeks
Number of subjects: 674

Group type: COMPARATOR
Intervention: Vehicle control applied twice daily for 24 weeks
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: 1.5% ruxolitinib cream applied throughout 52 weeks
Number of subjects: 674

Group type: COMPARATOR
Intervention: Vehicle control applied throughout 52 weeks
Number of subjects: 674
Study: 36260828

Group type: COMPARATOR
Intervention: Temozolomide
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Capecitabine and Temozolomide
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: MGMT deficiency
Number of subjects: 144
Study: 36261015

Group type: EXPERIMENTAL
Intervention: T cell bispecific antibodies (TCBs) targeting gastric CEA
Number of subjects: 0
Study: 36261215

Group type: EXPERIMENTAL
Intervention: Amplivant-conjugated HPV16-SLP vaccine (1, 5, 20 or 50 µg per conjugated peptide)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Amplivant-conjugated HPV16-SLP vaccine (highest dose group)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Amplivant-conjugated HPV16-SLP vaccine (various doses)
Number of subjects: 25
Study: 36261307

Group type: COMPARATOR
Intervention: Postoperative delirium
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Total study population
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Patients with decreased functional connectivity strength
Number of subjects: 554

Group type: COMPARATOR
Intervention: Patients with and without postoperative delirium
Number of subjects: 554
Study: 36261583

Group type: EXPERIMENTAL
Intervention: Serplulimab 3 mg/kg every 2 weeks for up to 52 cycles
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Serplulimab
Number of subjects: 108
Study: 36261602

Group type: EXPERIMENTAL
Intervention: Active treatment (revascularization and/or intestinal resection)
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Exploratory laparotomy or laparoscopy
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: End-of-life care
Number of subjects: 577

Group type: COMPARATOR
Intervention: Overall hospital management
Number of subjects: 577
Study: 36261752

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for high-risk stage II and stage III patients
Number of subjects: 3544

Group type: EXPERIMENTAL
Intervention: Curative-intent treatment
Number of subjects: 3544

Group type: COMPARATOR
Intervention: Palliative treatment
Number of subjects: 3544

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 3544
Study: 36261825

Group type: EXPERIMENTAL
Intervention: Back Rx mobile application for discogenic chronic low back pain
Number of subjects: 75